EUSA Pharma Receives Positive CHMP Opinion for Tivozanib
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA ® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC). EUSA's marketing authorisation application included data from the TiVO-1 pivotal study, which included over 500 patients with advanced RCC.07/12/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | European Medicines Agency (EMA) | Kidney Cancer | Marketing | Pharmaceuticals | Renal Cell Carcinoma | Study | Urology & Nephrology